What one share of Akari Therapeutics holds
We are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) designed around novel, proprietary cancer-killing toxins (“payloads”). We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
Akari Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.00 |
|---|---|
| Cash and investments | $0.00 |
| Book value | $0.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$0.06 | $0.00 | −$0.03 | — | −$0.18 |
| 2011 | — | −$0.18 | $0.00 | −$0.08 | — | −$0.21 |
| 2012 | — | −$0.35 | $0.00 | −$0.17 | — | −$0.25 |
| 2013 | — | −$0.17 | $0.00 | −$0.26 | — | $0.01 |
| 2014 | — | −$0.02 | $0.00 | −$0.02 | — | — |
| 2015 | — | −$0.05 | $0.00 | −$0.01 | — | $0.04 |
| 2016 | — | −$0.02 | $0.00 | −$0.02 | — | $0.03 |
| 2017 | — | −$0.03 | $0.00 | −$0.03 | — | $0.01 |
| 2018 | — | −$0.01 | $0.00 | −$0.01 | — | — |
| 2019 | — | −$0.01 | $0.00 | −$0.01 | — | $0.00 |
| 2020 | — | −$0.01 | — | — | — | $0.00 |
| 2021 | — | −$0.00 | — | — | — | $0.00 |
| 2022 | — | −$0.00 | — | — | — | $0.00 |
| 2023 | — | −$0.00 | — | — | — | $0.00 |
| 2024 | — | −$0.00 | — | — | — | — |
| 2025 | — | −$0.00 | — | — | — | $0.00 |
Common questions about Akari Therapeutics
How much does one share of Akari Therapeutics earn?
Over the last 12 months, Akari Therapeutics lost $0.00 for each share.
Does Akari Therapeutics pay a dividend?
Akari Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Akari Therapeutics’s book value per share?
Akari Therapeutics’s book value is $0.00 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Akari Therapeutics have?
Each share of Akari Therapeutics has $0.00 of cash and investments, as of June 30, 2026.
Has Akari Therapeutics bought back shares?
Akari Therapeutics’s share count rose about 589444% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.